CIVILICA We Respect the Science
Publisher of Iranian Journals and Conference Proceedings
Paper
title

Exome sequencing reveals a novel mutation in BBS2 gene in an Iranian family diagnosed with Bardet-Biedl Syndrome

Credit to Download: 0 | Page Numbers 1 | Abstract Views: 666
Year: 2014
COI code: CIGS13_0906
Paper Language: English

How to Download This Paper

For Downloading the Fulltext of CIVILICA papers please visit the orginal Persian Section of website.

Authors Exome sequencing reveals a novel mutation in BBS2 gene in an Iranian family diagnosed with Bardet-Biedl Syndrome

  Mahsa Fadaee - Genetics Research Centre, University of Social Welfare and Rehabilitation Sciences, Tehran, Iran.
  Zohreh Fattahi - Genetics Research Centre, University of Social Welfare and Rehabilitation Sciences, Tehran, Iran Kariminejad - Najmabadi Pathology & Genetics Center, Tehran, Iran.
Mohammad Reza Akbari - Women’s College Research Institute, University of Toronto, Toronto, ON, Canada.
Yousef Shafeghati - Sarem Cell Research Center (SCRC), Sarem Women’s Hospital, Tehran, Iran.

Abstract:

Rare autosomal recessive Bardet-Biedl Syndrome (BBS) is a kind of pleiotropic ciliopathies which is more common in developing countries. BBS is characterized by symptoms including obesity, retinitis pigmentosa, polydactyly, learning problems, hypogonadism and kidney abnormalities that vary both within and between families. Nineteen disease-causinggenes are involved in 80% of BBS cases and code proteins localized to the cilia which each function affect different parts ofa cilium. BBS2 in contribution with six most conserved BBS genes, form BBSome complex of the cilium.Here, we report an Iranian family with a ciliopathy disorder ascribing BBS. Whole exome sequencing (WES) was performed for proband which revealed a novel homozygote splice mutation c.535-1 G>C in BBS2 gene that would probably lead to skipping of exon 5. Using bioinformatics software, Mutation Taster, predicts c.535-1 G>C as a disease causingvariant. WES data were confirmed by Sanger sequencing and co-segregation was performed for his family.Estimating about 8% of BBS reports, BBS2 is among one of the common genes in BBS (same results in Iranian populationunpublisheddata). This result was in accordance with our expectations. In conclusion, due to the clinical and geneticheterogeneity observed in Bardet-Biedl syndrome WES could be considered as the method of choice for clinical genetics practice

Keywords:

Bardet-Biedl syndrome, BBS2 gene, whole exome sequencing, Sanger sequencing, Iran

Perma Link

https://www.civilica.com/Paper-CIGS13-CIGS13_0906.html
COI code: CIGS13_0906

how to cite to this paper:

If you want to refer to this article in your research, you can easily use the following in the resources and references section:
Fadaee, Mahsa; Zohreh Fattahi; Mohammad Reza Akbari & Yousef Shafeghati, 2014, Exome sequencing reveals a novel mutation in BBS2 gene in an Iranian family diagnosed with Bardet-Biedl Syndrome, 12th Congress of Iranian Genetics Society, تهران, انجمن ژنتيك ايران, https://www.civilica.com/Paper-CIGS13-CIGS13_0906.htmlInside the text, wherever referred to or an achievement of this article is mentioned, after mentioning the article, inside the parental, the following specifications are written.
First Time: (Fadaee, Mahsa; Zohreh Fattahi; Mohammad Reza Akbari & Yousef Shafeghati, 2014)
Second and more: (Fadaee; Fattahi; Akbari & Shafeghati, 2014)
For a complete overview of how to citation please review the following CIVILICA Guide (Citation)

Scientometrics

The University/Research Center Information:
Type: state university
Paper No.: 860
in University Ranking and Scientometrics the Iranian universities and research centers are evaluated based on scientific papers.

Research Info Management

Export Citation info of this paper to research management softwares

New Related Papers

Iran Scientific Advertisment Netword

Share this paper

WHAT IS COI?

COI is a national code dedicated to all Iranian Conference and Journal Papers. the COI of each paper can be verified online.